Pharma

The big (shrinking) short list

What are we looking for?: Canadian companies with a reduction in short interest The screen Short-selling, or “shorting”, refers to the investment practice of borrowing shares and subsequently selling them in the hope that the shares will eventually decline, so that the borrower can buy the sh ...

Buy Cannabis Wheaton for 89% upside, says Mackie Research

Continued execution at Cannabis Wheaton Income Corp. (TSXV:CBW) has Mackie Research Capital analyst Greg McLeish feeling bullish about the stock. In a research update to clients today, McLeish maintained his “Buy” rating and one-year price target of $3.00 on CBW, implying a return of 88.7 per ...

Q1 2018 Share Price Performance

Analysis: Healthcare Outperforms the Market Starting this quarter, the Bloom Burton equity research team has taken over responsibility for the “Share Price Performance for the Canadian Healthcare Sector” blog from Wayne Schnarr. With the blog, Wayne created an essential light-reading but infor ...

Zymeworks has a 64 per cent upside, Paradigm Capital says

With a lead drug candidate in a Phase 1 clinical trial and a newly expanded partnership with Japanese pharma company Daiichi Sankyo, Zymeworks (TSX, NYSE:ZYME) deserves a big target price raise, says analyst Rahul Sarugaser from Paradigm Capital, who on Thursday reiterated his “Buy” rating with ...

Reducing drug prices in Canada might prove costly

Author: Steven Globerman U.S. pharmaceutical innovation has been disproportionately funded by U.S. consumers of patented drugs. Read more about Reducing drug prices in Canada might prove costly Tags:  American pharmaceutical prices prescription drugs drugs drug prices innovation healt ...

Don’t believe the hype about Amazon, this investor says

Amazon’s (NASDAQ:AMZN) dominance in the e-commerce space may be unparalleled but there’s only so much more growth available for the online behemoth, says Darren Sissons of Campbell, Lee & Ross, who claims the law of large numbers will keep investors from making big gains on this stock from here ...

How Pharmaceutical Blockchain Technology Challenges Can Be Overcome

By Ed Lamb, DrugPatentWatch Writer Pilot projects are underway, but regulatory and stakeholder buy-in concerns remain When pharmaceutical supply chain stakeholders met recently to discuss applications for blockchain technology, they… The post How Pharmaceutical Blockchain Technology Challenges Ca ...

OrganiGram is a buy, Canaccord Genuity says

OrganiGram Holdings’ (TSXV:OGI) newly announced acquisition of part ownership in a German cannabis company is a good play in terms of diversification, says Matt Bottomley, analyst for Canaccord Genuity, who in a research update on Tuesday reiterated his “Speculative Buy” rating and $5.50 targ ...

Profiting from Weak Earnings

Analysts will tell you that this earnings season has been a great success. In fact, many companies exceeded earnings expectations and were handsomely rewarded by the market. However, there were also plenty of companies that missed earnings expectations and/or provided worse than expected guidance, ...

Amazon’s stock is not as expensive as it seems, this fund manager says

Rob Lauzon There may be some questionable stocks in your portfolio but Amazon (NASDAQ:AMZN) isn’t one of them, says Rob Lauzon of Middlefield Capital Corporation, who claims that the online behemoth would have huge earnings if it didn’t keep feeding its massive expansion plans. Shares of Amazo ...